Cencora Stock: Strong Q3 Earnings and Bullish Analyst Consensus
ByAinvest
Tuesday, Nov 11, 2025 7:58 am ET1min read
COR--
Cencora, a pharmaceutical sourcing and distribution company, has outperformed the broader market with a 62.3% YTD gain and 46.8% over the past 52 weeks. The company has a market cap of approximately $69.9 billion and operates through the U.S. Healthcare Solutions and International Healthcare Solutions segments. Analysts expect Cencora to deliver an adjusted EPS of $17.64 for fiscal 2026, up 10.3% year-over-year, and the consensus rating is a "Strong Buy" based on 11 "Strong Buys" and four "Holds."
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet